Mucous membrane pemphigoid (MMP), also known as cicatricial pemphigoid, refers to a group of rare chronic autoimmune blistering diseases that predominately affect the mucous membranes, including the conjunctiva, and occasionally the skin. Patients with cutaneous involvement present with tense blisters and erosions, often on the head and the neck or at sites of trauma. Scarring of the mucous membranes is common, hence the designation cicatricial, which can lead to decreased vision, blindness, and supraglottic stenosis with hoarseness or airway obstruction. The first international consensus on mucous membrane pemphigoid was published in 2002. 
See the illustration below depicting ocular mucous membrane pemphigoid.
Classification of mucous membrane pemphigoid patients has been difficult because some patients with other autoimmune blistering diseases, including bullous pemphigoid (BP),epidermolysis bullosa acquisita (EBA),and anti-p200 pemphigoid, may have mucosal involvement. Also, clinical heterogeneity exists in the clinical manifestations of this disease, with some patients presenting with ocular involvement and others with oropharyngeal involvement. The heterogeneity in clinical manifestations does not appear to be linked to the heterogeneity of the target antigens alone.
As in other autoimmune diseases, environmental factors combined with genetic susceptibility lead to development of autoantibodies. By direct immunofluorescence (DIF) study, antibodies bound in a linear band at the epidermal-dermal junction have been found in patients with mucous membrane pemphigoid (MMP), as depicted below. By immunoelectron microscopy, these antibodies are found in the lamina lucida. In some patients, autoantibodies extend to the lamina densa. When detectable, circulating autoantibodies are present in a low titer. See the image below.
Different epithelial membrane zone components have been recognized by antibodies in patients with mucous membrane pemphigoid, including BP antigens 1 and 2 (BP230 and BP180), laminin-332, laminin-311, type VII collagen, b4 integrin subunit, and antigens with unknown identities (a 45-kd protein, uncein, a 168-kd epithelial protein, and a 120-kd epithelial protein). While circulating autoantibodies in a given patient tend to target a single antigen, sera of patients with same clinical features may target different autoantigens.
The incidence of mucous membrane pemphigoid (MMP) has been estimated to be 2 cases per million in studies performed in France and Germany. [2, 3, 4] Pure ocular mucous membrane pemphigoid occurs in less than 1 case per million in the United Kingdom.  . Among white patients in the United States, mucous membrane pemphigoid is associated with human leukocyte antigen DQB1*0301 (HLA-DQB1*0301). [6, 7]
No racial predilection is known.
Most studies have demonstrated a female-to-male ratio of approximately 2:1
Most patients with mucous membrane pemphigoid are elderly, with a mean age of 62-66 years.
Extensive studies on the long-term outcome of patients with mucous membrane pemphigoid (MMP) have not been performed.
In general, mucous membrane pemphigoid is a chronic, progressive disorder that responds poorly to therapy. Some patients may experience long-term remissions. The disease is characterized by intermittent exacerbations and waning of disease activity. Mucous membrane pemphigoid is a chronic blistering disease that frequently heals with scarring. Individual blisters may itch, and subsequent erosions are often painful. Depending on the sites affected, sequelae include decreased vision or blindness, hoarseness, esophageal stenosis, or upper airway compromise. This disease is often recalcitrant to therapy.
A cohort study of 35 patients with anti–laminin-332 mucous membrane pemphigoid indicated an increased risk of malignancy that approximates that for adults with dermatomyositis. The risk is particularly high in the first year of disease.
Be certain that patients understand the chronic nature of this disorder.
Help patients in identifying factors that precipitate disease activity, and instruct them to avoid conditions that exacerbate the condition.
Discuss the medications, including the dose, the adverse effects, and the symptoms of toxicity, with the patient.
Teach patients appropriate wound care.
What would you like to print?